Last updated on February 2019

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia


Brief description of study

The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.

Clinical Study Identifier: NCT02832037

Contact Investigators or Research Sites near you

Start Over

Boehringer Ingelheim Call Center

CNRI - Los Angeles
Pico Rivera, CA United States
0.62miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.